Navigation Links
EntreMed To Raise $10.7 Million In Registered Direct Offering
Date:3/1/2013

d warrants to be issued in this transaction (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and declared effective.  A prospectus supplement relating to the offering will be filed by EntreMed with the SEC.  Copies of the prospectus and prospectus supplement and accompanying prospectuses may be obtained directly from Burrill Securities LLC, Prospectus Department, One Embarcadero Center, Suite 2700, San Francisco, CA 94111, 415-591-5400 or email: wwang@b-c.com.  This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of EntreMed.  No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed recently announced the initiation of a Phase 2 study of ENMD-2076 in triple-negative breast cancer and the initiation of a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the SEC.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a d
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
9. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
10. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
11. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 /PRNewswire/ ... Co., Ltd. (Headquarters: Tokyo , President ... Therapeutics, Inc. (Headquarters: San Diego, California ... "NASDAQ: HALO") have signed a clinical collaboration agreement to ... "eribulin") in combination with Halozyme,s investigational drug PEGPH20 (PEGylated ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) today announced that it ... FDA Panel meeting on Monday, May 10, 2010 at ... . Don Bailey , President and Chief Executive Officer; Steve ... , Chief Science Officer; and Dr. Jason Zielonka , Senior Vice President ...
... , May 3 Watson Pharmaceuticals, Inc. (NYSE: WPI ... Watson,s president and chief executive officer, will provide an overview and update of ... Tuesday, May 11, 2010 at 1:40pm Eastern Daylight Time ... , , ...
Cached Medicine Technology:Questcor to Discuss Results From FDA Panel Meeting 2Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference 2
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... ... is a reputable source of authentic USA vs. Australia tickets at Ford Field ... Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup ... was awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... ... July 31, 2015 , ... A family-run business in ... from ingredients sourced all over the world, then manufactured into specific formulations in ... developed the highest-quality oils in the industry, which we are bringing to consumers ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... PHILADELPHIA Scientists and clinicians from around the ... at the American Association for Cancer Researchs second ... Development. The conference is subtitled Maximizing Opportunities for ... diagnostics to provide new strategies for tailoring therapies ...
... LOMA LINDA, Calif., Sept. 10 Loma ... Day Adventist institution located,in Southern California, has ... physician referrals and outbound reminder calls for ... seeking physician referrals for breast care, psychology, ...
... Harvard Medical School,researchers have honored BlueCross BlueShield of ... providers to obtain member pre-,certifications in seconds over ... less costly. Researchers from the medical school,s ... tool as one of seven national,BlueWorks(R) winners in ...
... ABBOTT PARK, Ill., Sept. 10 Abbott (NYSE:,ABT) ... named to the Dow Jones,Sustainability World Index and ... third consecutive year. This selection recognizes Abbott,s,continued leadership ... is a critical part of our approach to ...
... ATLANTA, Sept. 10 Coalition America, Inc. (CAI),announces ... strategy officer who,will lead the deployment efforts of ... continuous new product development,initiatives. Brown comes to ... the,healthcare industry having held management roles in various ...
Cached Medicine News:Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Scientists, physicians present latest findings in 'personalized' cancer treatment and prevention 2Health News:Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Women's Services Programs and Departments 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2Health News:Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer 2
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Medicine Products: